A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: MK-8189
DRUG: Placebo
DRUG: Background AAP Therapy

Sponsor

Merck Sharp & Dohme LLC